Recent Advances In Evidence Based Cancer Starvation Strategies

Starving Cancer Cells: Evidence-Based Strategies to Slow Cancer Progression — A Selection of Readings for Health Services Providers presents an edited and annotated collection of recent medical journal publications and abstracts illustrating new approaches to treatment derived from the metabolic theory of cancer. It intends to shed an early light on a relatively new approach to our understanding of the cancer cell idiosyncratic metabolic dysfunction, and on evidence-based new treatment strategies derived from that understanding. The book discusses topics such as tumor starvation by L-arginine deprivation; L-canavanine depriving tumors of L-arginine in pancreatic, multiple myeloma and breast cancer; glucose deprivation and intermittent fasting; glutamine uptake in cancer; the relation of oxygen-starved cancer cells with aspartate; and reducing tolerance of tumor cells to nutrition starvation. The content is presented in a contextualized and practical way in order to facilitate the transition from bench to bedside. This is a valuable resource for practitioners, oncologists and other members of healthcare chain who are interested in learning more about the most recent tumor cell starvation strategies and how they can improve overall treatment outcome. Provides extensive comments on scientific publications detailing recent findings about tumor cell auxotrophy applied to tumor cell starvation strategies Helps the reader to find relevant and practical information on cancer cell starvation, otherwise spread through niched specialized journals, in one single place Comments on the recent findings putting them in context of clinical practice in order to provide the reader with means of translating high level research to the clinics

The book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism. However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requring metabolic solutions for its management and prevention. Support for this position is derived from critical assessment of current cancer theories. Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate.

This open access volume will introduce recent discoveries in cancer metabolism since the publication of the first edition in 2018, providing readers with an up-to-date understanding of developments in the field. Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, the authors delve into the complexity and diversity of cancer metabolism and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies for cancer treatment. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer treatment. This book has four major parts. Part one will cover the basic metabolism of cancer cells, followed by a discussion of the heterogeneity of cancer metabolism in part two. Part three addresses the relationship between cancer cells and cancer-associated fibroblasts, and the new part four will explore the metabolic interplay between cancer and other diseases. This new section makes the book unique from other texts currently available on the market. The second edition will be useful for cancer metabolism researchers, cancer biologists, epidemiologists, physicians, health care professionals in related disciplines, policymakers, marketing and economic strategists, among others. It may also be used in courses such as intro to cancer metabolism, cancer biology, and related biochemistry courses for undergraduate and graduate students.

With today's focus on targeted and minimally invasive therapies, photodynamic therapy (PDT) is now being studied and used to combat many disease states and to investigate critical biological questions. This groundbreaking resource brings you the latest advances in photodynamic therapy and offers you a solid understanding of the design, delivery and dosimetry of the three basic ingredients of PDT - photosensitizers, light and oxygen. The book covers novel areas of mechanistic and innovative translational approaches. Moreover, it gives you an overview of the important medical applications of PDT, including approved treatments, clinical trials, and investigated therapies for cancer and non-malignant diseases.

"Jane McLelland was only 30 when she was diagnosed with cancer. A few years later it was stage 4 (or terminal) and had spred to her lungs. Expected to live 12 weeks, she refused to believe there weren't any effective drugs or therapies. Her scientific training meant she was able to examine and digest hundreds of research papers she found in libraries, journals and online - and the conclusion she reached astonished her ... This is the story of how she took on her illness, changed her diet, educated herself, persuaded her oncologist and other doctors to prescribe her an unusual cocktail of commonly used drugs - some of which are already in many people's medicine cabinets - these made the difference between life and death ..."--Publisher description.

This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.

Starting with discussion of basic concepts and the molecular mechanisms of necrosis, this book looks first at several forms of necrotic cell death that have been identified, including necroptosis, autophagic cell death, and PARP-mediated cell death. As necrotic cell death is increasingly known to play a critical role in many physiological processes, the next chapters discuss its effect on metabolism, inflammation, immunity, and development. Necrotic cell death is closely implicated in human diseases like cancer, so the next chapters examine its relevance to human diseases, and final chapters cover methodologies for measuring necrosis. This book presents comprehensive coverage of necrosis from recognized experts from leading academic and medical institutions around the world. ​In contrast to apoptosis, well-defined as a form of programmed cell death, necrosis used to be considered as accidental (i.e., non-programmed) cell death, usually in response to a severe injury. Accumulating evidence now suggests, however, that necrosis is also programmed and controlled by distinctive "death machinery" in response to various stimuli like oxidative stress or DNA damage.

Cancer is clearly an age-related disease. Recent research in both aging and cancer has demonstrated the complex interaction between the two phenomena. This affects a wide spectrum of research and practice, anywhere from basic research to health care organization. Core examples of these close associations are addressed in this book. Starting with basic research, the first chapters cover cancer development, mTOR inhibition, senescent cells altering the tumor microenvironment, and immune senescence affecting cancer vaccine response. Taking into account the multidisciplinarity of geriatric oncology, several chapters focus on geriatric and oncologic aspects in patient assessment, treatment options, nursing and exercise programs. The book is rounded off by a discussion on the impact of the metabolic syndrome illustrating the interactions between comorbidity and cancer and a chapter on frailty.This book provides the reader with insights that will hopefully foster his or her reflection in their own research and practice to further the development of this most exciting field. Given the aging of the population worldwide and the high prevalence of cancer, it is essential reading not only for oncologists and geriatricians but for all health practitioners.